{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T17:59:22Z","timestamp":1757699962531},"reference-count":15,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,8,15]],"date-time":"2007-08-15T00:00:00Z","timestamp":1187136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Interven Cardiology"],"published-print":{"date-parts":[[2007,10]]},"abstract":"<jats:p> <jats:bold>\n            <jats:italic>Background:<\/jats:italic>\n          <\/jats:bold> Adverse events occur following non\u2010ST elevation acute coronary syndromes (NSTE ACS). However, the timing of these events in relation to index event is less clear.<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Methods:<\/jats:italic>\n          <\/jats:bold> Accordingly, we evaluated 26,466 NSTE ACS patients from the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO\u2010IIb), Platelet Glycoprotein IIb\/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT), and Platelet IIb\/IIIa Antagonism for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network (PARAGON) A and B trials to ascertain the timing of adverse events. Outcomes of interest were death, myocardial infarction (MI), and death or MI at 180 days. Logistic regression modeling for death was used to categorize patients into low\u2010, medium\u2010, and high\u2010risk groups.<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Results:<\/jats:italic>\n          <\/jats:bold> At 6 months, 6.2% of patients died, 12.1% had MI, and 15.7% suffered death or MI. From 15% to 40% of these events occurred beyond 30 days. At 6 months, 3%, 4%, and 13% of patients died in low\u2010, medium\u2010, and high\u2010risk groups, respectively. However, the proportion of patients dying beyond 30 days was similar in the three groups (44%, 43%, and 41% of death, respectively). Similarly, whereas death or MI increased with higher risk (11%, 14%, and 23%, respectively), the proportion of patients with this event beyond 30 days did not differ in the three strata (22%, 20%, and 25%, respectively).<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Conclusions:<\/jats:italic>\n          <\/jats:bold> Our study provides important insights into the timing of adverse events and suggests that the substantial proportion of patients suffer subsequent adverse events after their index NSTE ACS. Thus, these data call for continuous surveillance for these events and efforts beyond the acute phase at increasing adherence to evidence\u2010based therapies to improve the outcomes of these patients.<\/jats:p>","DOI":"10.1111\/j.1540-8183.2007.00277.x","type":"journal-article","created":{"date-parts":[[2007,8,17]],"date-time":"2007-08-17T00:59:26Z","timestamp":1187312366000},"page":"299-306","source":"Crossref","is-referenced-by-count":3,"title":["Timing of Death and Myocardial Infarction in Patients with Non\u2010ST Elevation Acute Coronary Syndromes: Insights From Randomized Clinical Trials"],"prefix":"10.1111","volume":"20","author":[{"given":"RAJENDRA H.","family":"MEHTA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ADAM B.","family":"GREENBAUM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YULIYA","family":"LOKHNYGINA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. KRISTIN","family":"NEWBY","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FRANS","family":"VAN DE WERF","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PAUL W.","family":"ARMSTRONG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KAREN S.","family":"PIEPER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ROBERT M.","family":"CALIFF","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHRISTOPHER B.","family":"GRANGER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ROBERT A.","family":"HARRINGTON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,8,15]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"13","volume-title":"Detailed Diagnosis and Procedures: National Hospital Discharge Survey, 1996","author":"National Center for Health Statistics","year":"1998"},{"key":"e_1_2_6_3_2","unstructured":"AntmanE AnbeDT ArmstrongPW et al.ACC\/AHA guidelines for the management of patients with ST\u2010elevation myocardial infarction: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction).2004. Available athttp:\/\/www.acc.org\/clinical\/guidelines\/stemi\/index.pdf. Accessed July 23 2006."},{"key":"e_1_2_6_4_2","first-page":"2557","article-title":"Predictors of outcomes in patients with acute coronary syndromes without persistent ST elevations","volume":"101","author":"Boersma E","year":"2000","journal-title":"Circulation"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.7.835"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.19.2345"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.18.1860"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199609123351103"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808133390704"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.24.2386"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/hc0302.102573"},{"key":"e_1_2_6_12_2","first-page":"1915","article-title":"Effect of glycoprotein IIb\/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: The GUSTO IV\u2010ACS randomised trial","volume":"357","year":"2001","journal-title":"The GUSTO IV-ACS Investigators"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106213442501"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91270-2"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.2.149"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.18.2027"}],"container-title":["Journal of Interventional Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1540-8183.2007.00277.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1540-8183.2007.00277.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T07:21:27Z","timestamp":1697354487000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1540-8183.2007.00277.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,15]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["10.1111\/j.1540-8183.2007.00277.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1540-8183.2007.00277.x","archive":["Portico"],"relation":{},"ISSN":["0896-4327","1540-8183"],"issn-type":[{"value":"0896-4327","type":"print"},{"value":"1540-8183","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,15]]}}}